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ABSTRACT 
 
Background: Myeloma patients experience the longest diagnostic delays compared with other 
cancers in the UK; 37% are diagnosed through emergency presentations. 
 
Aim: To identify and quantify the risk of myeloma from specific clinical features reported by primary 
care patients.  
 
Design and setting: Matched case-control study using General Practice Research Database primary 
care electronic records.  
 
Methods: Putative clinical features of myeloma were identified and analysed using conditional 
logistic regression. Positive predictive values (PPVs) were calculated for the consulting population. 
 
Results: 2,703 patients aged ≥40 years, diagnosed with myeloma between 2000 and 2009, and 
12,157 age, sex and general practice-matched controls. Sixteen features were independently 
associated with myeloma: hypercalcaemia, odds ratio 11.4 (95% confidence interval 7.1,18), 
cytopenia 5.4 (4.6,6.4), raised inflammatory markers 4.9 (4.2,5.8), fracture 3.1 (2.3,4.2), raised mean 
corpuscular volume 3.1 (2.4,4.1), weight loss 3.0 (2.0,4.5), nosebleeds 3.0 (1.9,4.7), rib pain 2.5 
(1.5,4.4), back pain 2.2 (2.0,2.4), other bone pain 2.1 (1.4,3.1), raised creatinine 1.8 (1.5,2.2), chest 
pain 1.6 (1.4,1.8), joint pain 1.6 (1.2,2.2), nausea 1.5 (1.1,2.1), chest infection 1.4 (1.2,1.6), and 
shortness of breath 1.3 (1.1,1.5).  Individual symptom PPVs were generally below 1%, though were 
over 10% for some symptoms when combined with leucopenia or hypercalcaemia.  
 
Conclusions: Individual symptoms of myeloma in primary care are generally low risk - probably 
explaining diagnostic delays. Once simple primary care blood tests are taken, risk estimates change. 
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Hypercalcaemia and leucopenia are particularly important abnormalities, and coupled with 
symptoms, strongly suggest myeloma. These results should aid doctors’ clinical decision making in 
selecting relevant patients for primary care testing, thereby reducing diagnostic delay. 
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HOW THIS FITS IN 
What is already known on this subject? 
 The UK performs poorly with respect to the European average in cancer survival.  Myeloma 
is no exception; indeed it ranks worst of the major cancers in terms of diagnostic delay.  
 Identifying myeloma in primary care is difficult as it is a multi-site cancer with varying 
symptoms; its salient clinical features in primary care have not previously been reported 
What this study adds 
 Many features may precede myeloma, but single symptoms have very low predictive values. 
However, when coupled with laboratory abnormalities, especially hypercalcaemia or 
leucopenia, the risk of myeloma is considerably increased. 
 These results should aid doctors’ clinical decision making in selecting relevant patients for 
primary care testing, thereby reducing diagnostic delay. 
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INTRODUCTION 
Multiple myeloma is a cancer of plasma cells. Over 4,700 cases are diagnosed annually in the UK, 
with a male to female ratio of 1.3:1. The incidence increases with age: 71% of UK cases are 
diagnosed in those aged 65 or more. (1) Myeloma is usually preceded by an asymptomatic phase of 
paraprotein secretion, termed monoclonal gammopathy of undetermined significance (MGUS). (2) 
The progression rate from MGUS to myeloma is approximately 1% annually. (3) The five year UK 
survival percentage is 37%: furthermore, the UK had an estimated 703 ‘avoidable’ myeloma deaths 
between 1995 and 1999, compared to the average European survival.(4, 5) Around 37% of UK 
myeloma patients are diagnosed as emergency presentations, with a poorer prognosis (51% 12-
month survival compared to 81% non-emergencies). (6, 7) This is one of the highest proportions 
among adult cancers. 
 
Identifying myeloma in primary care is a challenge. It is the cancer site with the highest percentage 
of patients consulting their GP three or more times before referral. (8) Diagnosis with advanced 
disease is frequent: 88% of non-emergency patients have complications at diagnosis. (9) Myeloma 
has myriad symptoms, which are often at multiple sites and non-specific, with musculoskeletal pain, 
fatigue and fractures often reported. (10) However, nearly all previous reports of the myeloma 
symptoms have originated from secondary care, where it is likely there is more advanced disease, 
with potentially different features, including hypercalcaemia, bone lesions, renal impairment and 
anaemia. (11) Current National Institute for Health and Clinical Excellence (NICE) diagnostic 
guidelines relate to haematological cancer as a whole. They recommend a full blood count and film, 
plus inflammatory markers for persistent unexplained fatigue, as well as investigation of spinal 
compression or renal failure – and, dependent upon severity - bone pain, breathlessness, recurrent 
infections and weight loss. (12) Early diagnosis of myeloma in primary care should be possible in 
theory: plasma viscosity (or other inflammatory markers) serum protein and protein electrophoresis 
6 
 
are generally available. (13) However, initiating investigation requires recognition of the possibility 
of myeloma.  
 
This study aimed to identify and quantify the early clinical features (symptoms, diseases and 
abnormal investigations) of myeloma in primary care, to guide general practitioners when to 
consider testing.  
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METHODS 
This was a matched case-control study using patient records from the UK’s General Practice 
Research Database (GPRD: now called the Clinical Practice Research Datalink). The GPRD is a large 
computerised database of anonymised patient data from over 600 UK general practices. (14) It is 
broadly representative of the UK population. Information is stored for clinical events such as 
symptom reporting, diagnostic testing, medical diagnoses, prescriptions and specialist referrals. Data 
quality is assured through adherence to strict recording guidelines. (15) 
 
Cases and controls 
Cases were selected if aged ≥40 years with a diagnosis of myeloma between January 2000 and 
December 2009.  The GPRD’s master code library has twenty-three separate myeloma codes (based 
on READ codes; available from authors).  Up to five age, sex and practice controls were matched to 
each case. The date of diagnosis was taken as the first myeloma code. This also served as the index 
date for the matched controls. Exclusion criteria were: any case or control with less than one year of 
records before the index date; cases without controls, controls with myeloma, and controls who had 
not sought medical care after registration. Some cases had paraproteinaemia ≥30g/l before their 
myeloma code (this level is diagnostic of myeloma, irrespective of any accompanying features). (16) 
There are two possible explanations for this: first, the patient was in the peri-diagnostic period, and 
was shortly to be given the myeloma label, or the practice had omitted to record myeloma. To 
accommodate both possibilities, a cut-off of 60 days was applied; retaining cases whose diagnostic-
level paraproteinaemia was solely recorded within 60 days of diagnosis, but excluding those with a 
longer interval.  
 
Selection of putative clinical variables 
Symptoms, diseases and abnormal investigations reported in the myeloma literature and from 
patient online support groups were studied; these are called ‘features’ from now on. PubMed, 
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EBSCO and Google were used with the search terms ‘myeloma symptoms’, ‘myeloma reported to 
GP’, and ‘early signs/indications/symptoms of myeloma’. The GPRD contains over 100,000 medical 
codes; several codes can potentially be associated with each feature. A symptom library of codes 
was compiled for each feature. Occurrences of features were identified in the year before the index 
date. Only those features present in ≥2% of cases or controls were retained (this was invariably 
cases).  Recording bias was tested on a condition thought to have no association with myeloma – 
varicose veins – to identify any difference in the rate of recording between cases and controls. 
Abnormal investigation results were defined as the patient having a test value falling outside their 
local laboratory’s normal range. Patients with a normal laboratory result were grouped with those 
who had not been tested.  
 
Composite variables 
Some tests were grouped together. The raised inflammatory markers variable was a composite of 
any of abnormal erythrocyte sedimentation rate, plasma viscosity, or C-reactive protein, as different 
local laboratories had local preferences for the inflammatory marker of choice; similarly abnormal 
liver function tests reflected a raised value of any of the hepatic enzymes reported by each 
laboratory. In clinical practice, haemoglobin, white cell count and platelets are normally requested 
together (‘the full blood count’). For our multivariable analyses, a composite variable ‘cytopenia’ was 
deemed to be positive if any of the haemoglobin, white cell count or platelets was abnormally low; 
for positive predictive values (see below) the three cell types were analysed separately.  Bone pain 
codes often had an anatomical descriptor as well as the words ‘bone pain’.  We retained ‘rib pain’, 
‘back pain’ and ‘joint pain’ as separate entities; remaining bone pain codes, such as ‘tibial pain’ were 
merged with the generic ‘bone pain’ code, making a group we called ‘combined bone pain’.  
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Analysis and statistical methods 
Analysis used non-parametric methods as the data was not normally distributed. Testing for 
association used univariable and multivariable conditional logistic regression, performed in three 
stages. (17-20) We did not include the variable for hypergammaglobulinaemia in the multivariable 
analyses as it could be considered an outcome variable rather than an explanatory variable.  The first 
stage, univariable analysis, used a p-value threshold of ≤0.1 to identify candidate variables for 
multivariable analysis. These were then grouped into small clinically coherent groups containing 
similar variables (such as back pain, rib pain and bone pain) in the first stage of multivariable 
analysis, with retention requiring a p-value ≤0.05. A final multivariable model used the surviving 
variables from the previous stages, using a p-value threshold of 0.01. Two variables, raised 
cholesterol and abnormally low mean corpuscular volume, were excluded from the final model as 
both proved to be protective, both with ORs of 0.6. Excluded variables were checked against the 
final model.  Clinically plausible interaction terms were added to the final model and retained if their 
p-value was also ≤0.01. A subsidiary analysis removed patients with a MGUS code in the year before 
the index date. These were repeated for patients up to age 60, and for ≥60.  
 
Risk estimates in the form of positive predictive values (PPVs) were calculated using Bayes’ theorem 
(prior odds x likelihood ratio = posterior odds). (21) Prior odds were calculated from the age-specific 
national incidence of myeloma for 2008, expressed as odds. PPVs for pairs of features and repeated 
attendances for the same feature were calculated where indicated. PPVs were estimated for 
consulting patients only: thus, the posterior odds were divided by 0.911 as 1,201 (9%) of 13,358 
eligible controls were non-consulters (see Figure 2).  
 
Power calculation 
The GPRD provided estimates of 3,000 cases and 15,000 controls; as this number was effectively 
fixed, we performed power calculations instead of sample size calculations. This provided >97% 
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power (5% two-sided alpha) to detect a change in a rare variable in 2% of cases and 1% of controls.  
For a commoner variable, the study had >95% power to detect a change in prevalence of 20% in 
cases to 17% in controls. Data analysis was conducted using Stata software, version 11. (22) 
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RESULTS 
The GPRD provided 16,233 patients (2,730 cases; 13,503 controls). Application of the exclusion 
criteria is shown in Figure 1, leading to a final number of 14,860 (2,703 cases; 12,157 controls). 
 
     Figure 1 here 
   
Patient demographic and consultation information is given in Table 1. Cases consulted significantly 
more frequently than controls in the year before diagnosis (p=<0.001; ranksum test). 
 
     Table 1 here 
       
Clinical features  
Sixty-two symptoms and twenty-two abnormal test results were considered initially. Sixteen 
remained significant in the final model. Their frequencies, univariable likelihood ratios and 
multivariable odds ratios are shown in Table 2. The proportion of patients with varicose veins did not 
differ between cases and controls (p<0.38). No significant interaction terms were found. From the 
2,703 cases, 2,241 (83%) had at least one of the final model features from Table 2 recorded.  MGUS 
was identified in 204 cases and 5 controls. The final model did not materially change with the 
exclusion of these patients. Cases aged ≥60 reported back pain significantly more than controls for 
up to six consultations (first occurrence, PPV 0.1(CI 0.1 to 0.2); sixth occurrence 0.9 (CI 0.4 to 1.9) – 
not in table). Hypercalcaemia and cytopenia had the highest odds ratios (11.4 and 5.4, respectively; 
see table 2). 
 
     Table 2 here 
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Positive predictive values 
Figure 2 shows the PPVs for single and combined symptoms, for patients aged ≥60; individual 
symptoms have low PPVs and few combined symptoms have PPVs >=1.0.  This figure omits blood 
tests, so that it shows the symptoms that could suggest to the GP that blood testing (for raised 
inflammatory markers) may be appropriate. Figure 3 shows the PPVs for symptoms combined with 
blood tests, again in patients aged ≥60. Hypercalcaemia in combination with almost all final model 
features greatly increased the risk of myeloma. PPVs for the under 60s are not shown as they are 
very small, and based on small numbers. 
 
Figure 2 here 
 
 
 
     Figure 3 here 
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DISCUSSION  
Summary   
This is the first primary care study investigating the features of multiple myeloma. Eleven symptoms 
and five abnormal investigations were associated with the disease. The risk estimates for individual 
and most combinations of symptoms were low, though back pain accompanying nosebleeds or rib 
pain had PPVs of over 1%. However, if hypercalcaemia was present, risks were considerably higher – 
the highest being over 10% for hypercalcaemia accompanying fracture, or various skeletal pain 
variables. Although several features of bone marrow suppression, such as anaemia, 
thrombocytopenia and leucopenia were associated with myeloma, the strongest associations were 
noted with leucopenia. This has a risk of over 10% when reported with fractures or nosebleeds.  
 
Strengths and limitations 
The main study strengths are its large sample size, its representativeness of UK practice, and its 
primary care setting. (19, 20, 23-25) This study – the largest reported – provided ample power to 
identify rare but potentially clinically relevant symptoms of myeloma, and allowed sub-analyses by 
age. The results are highly likely to be generalisable. The study period coincided with the automatic 
transmission of laboratory results, thereby greatly reducing the chance of recording error.  
The primary care setting is important. Up to this point, studies of the symptoms of myeloma have 
originated from secondary care, when patients have already been selected for referral – probably 
because blood tests have identified paraproteinaemia. Patients in the referred population are more 
likely to have advanced disease, with organ damage, particularly in the kidneys. If myeloma 
diagnosis is to be expedited the focus has to be on identifying the primary care features of the 
disease, and helping GPs to select patients for initial testing. Additionally, hypercalcaemia in primary 
care is rare,(26) and GPs may not always be aware of the link with myeloma.  
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The nature of our study meant that we were reliant upon the accuracy of GP data recording. 
Additionally, multiple GPRD codes can apply to each feature, though most features had a generic 
code which GPs used preferentially. Symptoms may have been under-recorded; this only affects the 
likelihood ratios (and thus the PPVs) if under-recording is more prevalent in either cases or controls: 
there is no reason to think this is the case. Cases attended their GP more often, so in theory, there 
are more opportunities for the doctor to record a symptom. Our additional analysis – of varicose 
veins – tested this, and identified no differential recording. Some pertinent information may have 
been recorded in the hidden section of the records (the so-called ‘free text’) but a previous cancer 
study suggested the loss of data in the free text was minor. (27) Again, there would have to be 
differential free text recording between cases and controls for this to matter, and again we have no 
reason to believe this is so. Finally, it is unusual to be able to calculate PPVs from a case-control 
study (as the population has been enriched by the study design). We side-stepped this by estimating 
the prior odds of myeloma from registry data. This technique is now well accepted. (28) 
  
Comparison with existing literature 
Myeloma patients experience the highest proportion of long diagnostic delays in primary care out of 
24 common cancers. This is consistent with our finding of cases consulting twice as often as controls. 
It probably represents unfamiliarity of GPs in diagnosing myeloma, compounded by alternative 
benign explanations for symptoms such as back pain. In theory, myeloma should be one of the easier 
cancers to diagnose as near-definitive testing (raised inflammatory markers) are easily available in 
primary care – once the possibility is considered.  Secondary care literature reports symptoms (bone 
pain, breathlessness, weight loss), signs (fractures, recurrent infections) and abnormal investigations 
(hypercalcaemia, low haemoglobin values) associated with myeloma. All were also significant in our 
study.  
Although there are no previous primary care reports to compare, a study of Scandinavian blood 
donors identified low haemoglobin values in the years before myeloma was diagnosed - we 
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confirmed this in the present study. (29) Anaemia as a clue to myeloma was also a highlight of an 
audit of delayed myeloma diagnoses. (9) 
 
Implications for practice 
The relative rarity of myeloma, coupled with the non-specific nature of the symptoms, means that 
individual symptoms have low PPVs, although these are higher when there are multiple symptoms. 
PPVs of paired symptoms with abnormal tests could not be calculated due to lack of numbers.  Rib 
pain has been regarded as a key symptom of myeloma for many years; however other skeletal pain 
variables, such as back pain, had odds ratios nearly as large, and they are much more common 
symptoms. This is even more so in the presence of a full blood count suggesting anaemia or 
leucopenia. Given that a quarter of people aged over 40 have a full blood count in any one year, (30) 
it is reasonable to suggest that a GP investigates any patient over 60 with bone pain, nosebleeds or 
weight loss, using a full blood count and viscosity. Backache is common, but again should be 
investigated, probably on a second rather than a first attendance. Hypercalcaemia per se has a low 
risk of myeloma (0.7%), but when coupled with any of the symptoms described above the risk is 
considerable, warranting definitive investigation.  
 
Conclusion 
No single symptom is a strong indicator of myeloma. Repeated occurrences of back pain or when 
combined with nosebleeds or rib pain suggest initial testing – of inflammatory markers - at the 
discretion of the GP. The risk of myeloma increases greatly with the presence of hypercalcaemia.  
Joint pain and rib pain in conjunction with leucopenia or hypercalcaemia also signify a high risk of 
myeloma. These findings should influence the current revision of the NICE guidelines. 
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Table 2.  Features of myeloma (all ages). 
Feature 
Cases, n (%)  
n=2703  
Controls, n (%)  
n=12157  
Likelihood ratio a  
(95% CI)  
Odds ratio in 
multivariable 
analysis b (95% CI)  
Symptoms 
Back pain:1-6  766 (28) 753 (6) 4.6 (4.2-5.0)  2.2 (2.0 to 2.4) * 
Chest pain:1-3  397 (15) 531 (4) 3.4 (3.0-3.8)  1.6 (1.4 to 1.8) * 
Chest infection:1-2 319 (12) 770 (6) 1.9 (1.7-2.1)  1.4 (1.2 to 1.6) * 
Shortness of breath:1-2  277 (10) 661 (5) 1.9 (1.7-2.2)  1.3 (1.1 to 1.5) *# 
Nausea  162 (6) 228 (2) 3.2 (2.6-3.9)  1.5 (1.1 to 2.1) ˜ 
Fracture 159 (6) 201 (2) 3.6 (2.9-4.6)  3.1 (2.3 to 4.2)  
Joint pain   118 (4) 358 (3) 1.5 (1.2-1.8)  1.6 (1.2 to 2.2) § 
Combined bone pain  108 (4) 112 (0.7)  4.3 (3.3-5.6)  2.1 (1.4 to 3.1) # 
Weight loss 107 (4) 86 (0.7)  5.6 (4.2-7.1)  3.0 (2.0 to 4.5)  
Rib pain   80 (3) 47 (0.4)  7.7 (5.4-11)  2.5 (1.5 to 4.4) # 
Nosebleeds  76 (3) 78 (0.6)  4.4 (3.2-6.0)  3.0 (1.9 to 4.7)  
Investigations 
Cytopenia 1309 (48) 1109 (9) 5.3 (5.0-5.7)  5.4  (4.6 to 6.4)  
Raised inflammatory markers 1146 (42) 753 (6) 6.8 (6.3-7.4)  4.9 (4.2 to 5.8)  
Raised creatinine  648 (24) 1021 (8) 2.9 (2.6-3.1)  1.8 (1.5 to 2.2)  
Raised mean corpuscular 
volume (MCV) 
347 (13) 250 (2) 6.2 (5.3-7.3)  3.1 (2.4 to 4.1)  
Hypercalcaemia 246 (9) 44 (0.35)  26 (18-35)  11.4 (7.1 to 18)  
 
 a the univariate likelihood ratio, showing the likelihood of having a specific symptom in a patient with 
myeloma, compared with the likelihood of having it in a patient without cancer 
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b in multivariate conditional logistic regression, containing all sixteen variables 
* The odds ratio for these four variables is for each attendance with the symptom; for back pain this is up to 
the sixth attendance, for chest pain the third, and for chest infection and shortness of breath to the second 
attendance. 
# p=0.001 § p=0.002 ˜ p=0.006  
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Figure 1. Application of exclusion criteria 
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Figure 2. Positive predictive values for myeloma symptoms in patients sixty years of age and over, 
for single and paired features. 
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Notes: The PPV is shown on the first line of each cell with the 95% confidence limits shown underneath.  PPVs 
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combined features, CIs were omitted.  The yellow shaded cells indicate a PPV of 1.0-1.9%; orange cells 2.0-
4.9% and red cells of 5% and over. The cells showing the same feature vertically and horizontally represent a 
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Figure 3. Positive predictive values for myeloma blood tests with symptoms in patients sixty years 
of age and over: risk estimate for single investigations and paired with symptoms. 
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